MedTrace Logo

Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

NCT00683332 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 621

Last updated 2011-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Conditions

  • Complicated Skin and Skin Structure Infections
  • Complicated Intra-abdominal Infections

Interventions

DRUG

Tigecycline (Tygacil)

This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683332 on ClinicalTrials.gov